Sanara MedTech, Inc. (SMTI)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Sanara MedTech, Inc. (SMTI)
Company Performance

Current Price

as of Oct 17, 2024

$30.99

P/E Ratio

N/A

Market Cap

$273.78M

Description

Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.

Metrics

Overview

  • HQFort Worth, TX
  • SectorHealth Technology
  • IndustryMedical Specialties
  • TickerSMTI
  • Price$30.99-0.99%

Trading Information

  • Market Cap$273.78M
  • Float34.70%
  • Average Daily Volume (1m)26,254
  • Average Daily Volume (3m)23,377
  • EPS-$0.78

Company

  • Revenue$72.41M
  • Rev Growth (1yr)27.97%
  • Net Income-$3.50M
  • Gross Margin84.55%
  • EBITDA Margin-8.89%
  • EBITDA-$1.79M
  • EV$248.81M
  • EV/Revenue3.44
  • P/EN/A
  • P/S3.66
  • P/B6.56
Documents
SEC Filings
8-K (2024-10-07)
8-K (2024-09-23)
8-K (2024-09-11)
8-K (2024-08-12)
8-K (2024-06-20)
8-K (2024-06-18)
8-K (2024-06-17)
8-K (2024-05-30)
8-K (2024-05-13)
8-K (2024-04-18)
8-K (2024-04-05)
8-K (2024-03-25)
8-K (2024-03-22)
8-K (2024-02-22)
8-K (2023-11-13)
8-K (2023-09-19)
8-K (2023-08-16)
8-K (2023-08-14)
8-K (2023-08-02)
8-K (2023-06-06)
8-K (2023-05-15)
8-K (2023-03-20)
8-K (2023-02-24)
8-K (2023-02-22)
10-Q (2024-08-12)
10-Q (2024-05-13)
10-Q (2023-11-13)
10-Q (2023-08-14)
10-Q (2023-05-15)
10-K (2024-03-25)
10-K (2023-03-20)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-14)
Earnings Report (2023-08-15)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Sanara MedTech Q3 ($32.50, +3.93) (2023-11-14T15:17:37Z)
Sanara MedTech reports Q3 adjusted net income ($0.1M) vs year-ago ($0.2M) ($28.55, 0.00) (2023-11-13T21:10:30Z)
Sanara MedTech announces the publication of a 5.3K patient study demonstrating a significant reduction in surgical site infections when CellerateRX surgical powder was used to promote wound healing ($32.31, 0.00) (2023-11-30T14:19:35Z)